| |
Public Act 103-0059 Public Act 0059 103RD GENERAL ASSEMBLY |
Public Act 103-0059 | SB0101 Enrolled | LRB103 25077 BMS 51412 b |
|
| AN ACT concerning regulation.
| Be it enacted by the People of the State of Illinois,
| represented in the General Assembly:
| Section 5. The Illinois Insurance Code is amended by | changing Section 356z.25 as follows: | (215 ILCS 5/356z.25) | Sec. 356z.25. Coverage for treatment of pediatric | autoimmune neuropsychiatric disorders associated with | streptococcal infections and pediatric acute onset | neuropsychiatric syndrome. A group or individual policy of | accident and health insurance or managed care plan that is | amended, delivered, issued, or renewed after July 18, 2017 | (the effective date of Public Act 100-24) shall provide | coverage for treatment of pediatric autoimmune | neuropsychiatric disorders associated with streptococcal | infections and pediatric acute-onset neuropsychiatric | syndrome, including, but not limited to, the use of | intravenous immunoglobulin therapy. | No group or individual policy of accident and health | insurance or managed care plan shall deny or delay coverage | for medically necessary treatment under this Section solely | because the insured, enrollee, or beneficiary previously | received any treatment, including the same or similar |
| treatment, for pediatric autoimmune neuropsychiatric disorders | associated with streptococcal infections or pediatric acute | onset neuropsychiatric syndrome, or because the insured, | enrollee, or beneficiary has been diagnosed with or receives | treatment for an otherwise diagnosed condition. | For the purposes of this Section, coverage of pediatric | autoimmune neuropsychiatric disorders associated with | streptococcal infections and pediatric acute onset | neuropsychiatric syndrome shall adhere to the treatment | recommendations developed by a medical professional consortium | convened for the purposes of researching, identifying, and | publishing best practice standards for diagnosis and treatment | of such disorders or syndrome that are accessible for medical | professionals and are based on evidence of positive patient | outcomes. Coverage for any form of medically necessary | treatment shall not be limited over a lifetime of an insured, | enrollee, or beneficiary, unless the patient is no longer | benefiting from the treatment, or by policy period. Nothing in | this Section prevents insurers from requesting treatment notes | and anticipated duration of treatment and outcomes. | For billing and diagnosis purposes, pediatric autoimmune | neuropsychiatric disorders associated with streptococcal | infections and pediatric acute onset neuropsychiatric syndrome | shall be coded as autoimmune encephalitis until the American | Medical Association and the Centers for Medicare and Medicaid | Services create and assign a specific code for pediatric |
| autoimmune neuropsychiatric disorders associated with | streptococcal infections and pediatric acute onset | neuropsychiatric syndrome. Thereafter, pediatric autoimmune | neuropsychiatric disorders associated with streptococcal | infections and pediatric acute onset neuropsychiatric syndrome | may be coded as autoimmune encephalitis, pediatric autoimmune | neuropsychiatric disorders associated with streptococcal | infections, or pediatric acute onset neuropsychiatric | syndrome. | If, at any time, the Secretary of the United States | Department of Health and Human Services, or its successor | agency, promulgates rules or regulations to be published in | the Federal Register or publishes a comment in the Federal | Register or issues an opinion, guidance, or other action that | would require the State, pursuant to any provision of the | Patient Protection and Affordable Care Act (Public Law | 111-148), including, but not limited to, 42 U.S.C. | 18031(d)(3)(B) or any successor provision, to defray the cost | of any coverage for pediatric autoimmune neuropsychiatric | disorders associated with streptococcal infections and | pediatric acute onset neuropsychiatric syndrome outlined in | this Section, then the requirement that an insurer cover | pediatric autoimmune neuropsychiatric disorders associated | with streptococcal infections and pediatric acute onset | neuropsychiatric syndrome is inoperative other than any such | coverage authorized under Section 1902 of the Social Security |
| Act, 42 U.S.C. 1396a, and the State shall not assume any | obligation for the cost of coverage for pediatric autoimmune | neuropsychiatric disorders associated with streptococcal | infections and pediatric acute onset neuropsychiatric | syndrome.
| (Source: P.A. 100-24, eff. 7-18-17; 100-863, eff. 8-14-18; | 101-488, eff. 8-23-19.)
| Section 99. Effective date. This Act takes effect upon | becoming law. |
Effective Date: 6/9/2023
|
|
|